Experimental Eye Drops Help Restore Light Perception in Blind Mice

August 29, 2026

Scientists have developed a new experimental approach that uses light-activated drugs to restore visual responses in mice with severe retinal degeneration, raising the possibility of a future treatment that could restore some forms of vision without gene therapy or implanted electronic devices. The findings were reported by researchers led by the Institute for Bioengineering of Catalonia (IBEC) and published in the Journal of the American Chemical Society.

A different strategy for damaged retinas

Many degenerative eye disorders occur when photoreceptor cells—the specialized cells that normally detect light—gradually disappear. Conditions such as age-related macular degeneration and retinitis pigmentosa can therefore severely reduce or eliminate vision.

Researchers took a different approach from conventional gene therapy. Instead of attempting to replace the damaged photoreceptors, they developed photoswitchable molecules designed to interact with surviving cells deeper within the retina.

The experimental compounds are known as prosthe6. They are designed to respond to light and imitate an important function normally performed by photoreceptors.

Eye drops produced encouraging results

Two compounds, prosthe6-12 and prosthe6-15, produced particularly promising results in animal experiments.

Researchers tested the compounds in mouse models representing retinal degeneration. Following treatment, previously blind mice regained an instinctive preference for darker areas instead of moving randomly between light and dark environments.

The behavior was important because the animals were not trained to respond to the visual stimulus. Their renewed preference for darkness indicated that they could detect light and use that information to guide their behavior.

Scientists also observed visual responses in blinded zebrafish larvae after treatment.

How the molecular treatment works

The technology is based on photopharmacology, in which a drug’s activity can be controlled by exposure to light.

The prosthe6 compounds act on ON-bipolar cells, which normally receive signals generated by photoreceptors. By targeting the mGlu6-related signaling system in these surviving retinal cells, the molecules can effectively provide a replacement signal when the original photoreceptors are gone.

The researchers describe the compounds as a type of “molecular prosthesis” because they attempt to restore part of the retina’s natural signaling process rather than bypassing the retina completely.

No implants or genetic modification

One of the most notable aspects of the research is the method of administration.

The compounds produced visual effects after being delivered directly into the eye. More importantly, the two leading candidates also showed activity after topical administration as eye drops in the animal experiments. The approach does not require genetic modification or an implanted electronic device.

The researchers also reported that the compounds could function under ordinary lighting conditions, including illumination comparable to indoor environments and daylight under overcast conditions.

Still far from a human treatment

Despite the encouraging findings, the research does not mean that blindness can currently be treated with these eye drops in humans.

The experiments were conducted in animal models, and the researchers say additional safety, formulation and durability studies are needed before potential human clinical trials can be considered. The scientists are working toward extending the duration of the restored visual response and advancing the technology toward clinical development.

The research team is also collaborating on translational development through Eyelumina, a spin-off initiative intended to help move the technology toward future clinical testing.

A potentially simpler future approach

Existing experimental strategies for retinal blindness include gene therapy, optogenetics and electronic retinal prostheses. Each approach has significant technical or medical limitations.

A drug that could restore light sensitivity through a relatively simple, non-invasive delivery method would therefore represent a major change if it eventually proves safe and effective in humans.

For now, the results remain an early-stage animal discovery, but the study demonstrates that surviving retinal circuitry may be capable of responding to light again when activated with specially designed molecules.